

Having trouble viewing this email? [View it in your browser.](#)



American Heart Association®
Center for Health
Technology & Innovation

Greetings,

The health tech sector is demonstrating exactly why innovation matters. From AI-driven diagnostics to next-generation digital platforms, the pace of advancement is accelerating—and so is the impact. This month, we highlight the strategic shifts, market signals and breakthrough technologies shaping the future of healthcare.

Visit <https://ahahealthtech.org/> to learn more about the Center and all the resources available to you.

ENTER AHA'S CHTI
HEALTH TECH COMPETITION

Apply now for a chance to be one of 5 finalists
presenting live at Scientific Sessions

Application Deadline: Friday, September 18 McCormick Place Convention Center - Chicago, IL November 7 - 9, 2026

The Time Is Now: Your Moment to Shine in Health Tech Innovation

The American Heart Association's [Health Tech Competition](#) is officially open to accept applications. Emerging companies advancing cardiovascular and brain health are invited to apply for the chance to pitch live at Scientific Sessions, November 7–9, 2026, in Chicago.

Five finalists will pitch live to prove both the science and the business behind their innovations to a panel of clinicians, researchers, investors and industry executives. Beyond competing for the title:

All Finalists Receive: National visibility, professional marketing assets, conference passes and invitations to exclusive AHA innovation programs.

The Overall Winner Earns: Expanded media promotion and a complimentary one-year membership in the prestigious [AHA Innovators' Network](#).

Applications close September 18, 2026. If you're building the future of heart and brain health, now's the moment to step forward!

[Apply here.](#)



Cardiologist and epidemiologist Dr. Donald M. Lloyd-Jones, American Heart Association president in 2021–22, received the Gold Heart Award, recognizing a lifetime of transformative contributions to cardiovascular health. Pictured with volunteer President Dr. Stacey Rosen and Dr. Clyde Yancy *(Photo by Tim Sharp Media)*

Celebrating AHA and CHTI Volunteer Who Has Transformed Global Heart Health Understanding and Care

During the COVID-19 pandemic, Dr. Donald Lloyd-Jones became a trusted voice for millions—speaking with media outlets worldwide to explain how the virus affects heart health and to reinforce the safety of vaccines. His presidency during 2021–22 was a defining moment, but Don's influence spans decades.

He helped establish the gold-standard framework for cardiovascular health with Life's Simple 7, later expanded to [Life's Essential 8](#), and has guided the Association's science, guidelines, and governance since 1997. His leadership has shaped how

clinicians, researchers, and the public understand and improve heart health.

For his extraordinary contributions, Don received the American Heart Association's highest volunteer honor, the Gold Heart Award.

Congratulations also to the CHTI's Health Technology Advisory Group Volunteer who was also recognized:

Tiffany M. Powell-Wiley, M.D., M.P.H., FAHA, FABMR

Louis B. Russell, Jr. Memorial Award

[Read more about Dr. Tiffany Powell-Wiley](#)

See the full list of awardees and read their inspiring [backstories](#).



Cadence Announces \$100M Series C to Scale AI-Driven Chronic Care

Cadence has secured \$100M in Series C funding, a major milestone that accelerates its mission to transform chronic disease treatment across the U.S. With support from Spark Capital, Thrive Capital, General Catalyst, Coatue, B Capital Group, and leading health systems, Cadence is expanding its clinical AI platform—already used by 100,000+ patients.

Cadence's AI monitors patients daily, flags risk early and enables clinicians to act fast. Results include fewer hospital admissions, lower costs, improved blood pressure control

and rapid response times. This new investment fuels Cadence's next chapter in scaling world-class chronic care nationwide and setting a new standard for how chronic disease is managed in America.

Read full [announcement](#).



Using Risk and Benefit to Inform Care in Cardiovascular-Kidney-Metabolic Syndrome

The latest AHA/ACC scientific statement highlights a major shift in how clinicians assess and manage cardiovascular-kidney-metabolic (CV-KM) risk. New prevention guidelines now recommend using the PREVENT risk equations to guide when to start or intensify therapies for hypertension, dyslipidemia, and broader CV-KM conditions. This reflects growing recognition that cardiovascular, kidney, and metabolic risks cluster together—and require a unified, evidence-based approach.

The 2026 CV-KM guideline introduces outcome-specific PREVENT thresholds to support staging, detect subclinical disease, and inform treatment decisions across cardiovascular disease, ASCVD and heart failure.

The statement also outlines the rationale behind these thresholds, the supporting evidence and the potential population-level impact. It offers practical guidance for using risk assessment as the foundation of shared decision-making and for improving awareness, communication and implementation of preventive therapies for people with or at risk for CV-KM syndrome.

Read the full Abstract [here](#).



AccurKardia receives patent for AI-ECG cardiac amyloidosis detection

Innovators' Network member [AccurKardia](#) has secured a U.S. patent for its AI-ECG system designed to detect cardiac amyloidosis from a standard 12-lead ECG, aiming to surface earlier signals for a disease that is frequently missed. The patented, explainable machine-learning approach spans all major amyloidosis subtypes and builds on the company's growing AI-ECG portfolio. While still investigational and not yet FDA-cleared, the technology could one day help identify amyloidosis earlier using ECG data patients already receive in routine care.

AccurKardia is now advancing toward broader validation, moving from single-site studies to large, multi-site datasets to ensure strong performance across diverse patient groups.

Read full announcement [here](#).



Startups selected to advance cardiovascular health innovation

Eight standout medtech and digital health companies have been selected for the American Heart Association's [Heart and Brain Health Accelerator](#), supported by the 2026 MedTech Innovator Accelerator. Chosen from a highly competitive global pool, these early- and mid-stage startups are advancing some of the most promising innovations in cardiovascular and neurological health.

Through this collaboration, American Heart Association Ventures and Studio Red will provide tailored mentorship, coaching and strategic support—while companies also gain full access to MedTech Innovator's network, funding pathways and industry visibility. The cohort includes technologies spanning neuromodulation for dementia, hybrid AFib ablation, neurovascular tools, acoustic breath biomarkers, robotic navigation, virtual CCTA, point-of-care biomarker testing, and AI-guided ablation.

Selected in part by an AHA advisory committee for innovation and clinical impact, these companies now qualify for the MedTech Innovator Competition Finals in Boston and will be featured in the inaugural MTI Index, recognizing top medtech innovators.

Read more [here](#).



Welcome New Innovators' Network Members

The Innovators' Network is a fee-based consortium of industry entrepreneurs, providers and health systems, researchers, pharma, device manufacturers, community and social support networks and payors.

Membership offers research collaboration, AHA brand affiliation, access to a network of volunteer and industry experts and participation at AHA industry events.

Join us in welcoming our newest members of the Innovators' Network!

[Alyf Health](#) - an AI-native healthcare platform specializing in cardiovascular care . Founded by an interventional cardiologist and an AI technology leader, the company's platform uses artificial intelligence to monitor heart health, predict medical crises, and bridge the gap between patients and clinicians.

[Olivo Sciences](#) - they license de-identified multimodal data — multi-omics, imaging, clinical, and wearable — and provide domain-trained AI models to support biopharma across the entire drug development cycle, from discovery and clinical trial development to post-marketing.

Members with non-product news (e.g., funding, trials, publications, exe hires), please send to Darcy Barrett, darcy.barrett@heart.org. Approved submissions will be published on ahahealthtech.org and/or LinkedIn.

Learn more about becoming a member of the Innovators' Network and view all members [here](#) .

Engage with the American Heart Association professional member, from research and science to pilots and real-world use. Fill out this short [Jot Form](#) to express the areas you are interested in collaborating. We'll feature these on the CHTI website and share with our network of scientists and researchers.

The banner features the American Heart Association logo and the text 'Center for Health Technology & Innovation'. The main title is 'AI Agents: From Chatbots to Patient Prescribing'. The date and time are 'Wednesday, July 8, 2026, at 12:00pm EST'. The speakers are listed as Joseph E. Villa (Bigbee Labs, Inc.), Fran Conti-Ramsden, MD, PhD (Megi health), Eric Rock (Percipio Health), and Severence MacLaughlin (Delorean Artificial Intelligence). The text 'Webinar Series' is at the bottom left.

Agentic AI Prescriptions?

You are invited to a discussion on "AI Agents: From Chatbots to Patient Prescribing".

Tune in live Wednesday, July 8, 2026 at 12:00pm EST.

Join us for an engaging conversation with:

Moderator:

- Joseph E. Villa, Founder, Bigbee Labs, Inc.

Speakers:

- Fran Conti-Ramsden, MD, PhD, Chief Medical Officer, Megi health
- Eric Rock, Co-founder and CEO, Percipio Health
- Severence MacLaughlin, Founder & CEO, Delorean Artificial Intelligence

Register to join live here:

https://heart.zoom.us/webinar/register/6717815533410/WN_lr7k5bDxQH29rLZH1L3X_g

Can't make it live? The content will be available [On Demand on AHA's You Tube](#) following the program.

We hope to see you then!

You can browse all past issues in our [newsletter archive](#) to catch up on key stories and insights. Make sure you're in the loop— [don't miss our news and updates section](#).

We are eager to hear from you. Send Darcy Barrett, darcy.barrett@heart.org , your ideas for what you want included in the monthly newsletter.

Know someone who wants to join our mailing list? Forward the "sign up for our mailing list" [link](#).

Until next month!



To be removed from this email/newsletter list, please use the link below and follow the instructions.

[Remove my address from only this email/newsletter list](#)

[Remove my address from all association mailings](#)

You will be removed from the email/newsletter list within 24 hours.

[Privacy Policy](#) | [Ethics Policy](#) | [Conflict of Interest Policy](#)

To unsubscribe via postal mail, please contact us at:

American Heart Association
Attn: Email Subscriptions Group
7272 Greenville Ave. Dallas, TX 75231